Anthropic launches drug discovery programs for neglected diseases

What happened

Anthropic announced it is launching its own drug discovery programs targeting neglected diseases that traditional pharma and biotech firms consider unprofitable. The company will focus on early, preclinical-stage drug development. Anthropic also unveiled Claude Science, a new AI tool for research, and demonstrated early examples including a UCSF researcher using it to spot a viral contamination in minutes that his team had missed for an entire year.

Why it matters

Pharma R&D timelines and success rates have long been constrained by information delays and operational bottlenecks. Novartis CEO Vas Narasimhan stated that AI tools could cut information and operational latency—which account for roughly 40 percent of total development time—potentially bringing drug development timelines down from twelve years to seven or eight years. Even modest improvements would matter: major pharma companies spend $150 to $200 billion（約32兆円） a year on R&D, and expanding the pool of treatable diseases could make previously unreachable drug targets viable.

What to watch

Claude Science analyzed 100 rare genetic diseases in under an hour and flagged 32 candidates for computational screening. Anthropic frames this drug discovery work as aligned with its nonprofit mission and as a way to build better AI models through firsthand experience in the sector. Other AI firms—including Deepmind (via Isomorphic Labs with Alphabet) and OpenAI—are also expanding into medicine and clinical tools.